Molecular Mechanisms of Hepatocellular Carcinoma

Insights to Therapy
  • Marie C. DeFrances
  • George K. Michalopoulos
Chapter
Part of the Current Clinical Oncology book series (CCO)

Abstract

The incidence of hepatocellular carcinoma (HCC) is increasing in the United States (1) and elsewhere (2). Because of its late presentation, its aggressiveness, and its limited response to therapy, HCC is a major cause of cancer death with possibly up to 1 million deaths yearly attributed to HCC worldwide (3). Current treatment modalities for HCC are only modestly successful with orthotopic liver transplantation or resection offering the best hope for long-term survival in select patients (3).

Keywords

Hepatocellular Carcinoma Hepatocyte Growth Factor Human Hepatocellular Carcinoma Adenomatous Polyposis Coli Gene Tocellular Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745–750.PubMedGoogle Scholar
  2. 2.
    Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1979–94. Lancet 1997;350:1142–1143.PubMedGoogle Scholar
  3. 3.
    Hussain SA, Ferry DR, El-Gazzaz G, et al. Hepatocellular carcinoma. Ann Oncol 2001;12:161–172.PubMedGoogle Scholar
  4. 4.
    Di Bisceglie AM, Carithers RL, Jr., Gores GJ. Hepatocellular carcinoma. Hepatology 1998;28:1161–1165.PubMedGoogle Scholar
  5. 5.
    Thorgeirsson SS. Mechanism(s) of hepatocarcinogensis: insight from transgenic mouse models. In: The Liver Biology and Pathobiology (Arias IM, ed.), Lippincott Williams & Wilkins, Philadelphia,2001, 1013–1028.Google Scholar
  6. 6.
    Puisieux A, Ozturk M. TP53 and hepatocellular carcinoma. Pathologie et Biologie 1997;45:864–870.PubMedGoogle Scholar
  7. 7.
    Salvucci M, Lemoine A, Saffroy R, et al. Microsatellite instability in European hepatocellular carcinoma. Oncogene 1999;18:181–187.PubMedGoogle Scholar
  8. 8.
    Buendia MA. Genetics of hepatocellular carcinoma. Semin Cancer Biol 2000;10:185–200.PubMedGoogle Scholar
  9. 9.
    Michalopoulos GK, DeFrances MC. Liver regeneration. Science 1997;276:60–66.PubMedGoogle Scholar
  10. 10.
    Kimura M, Ogihara M. Effects of insulin-like growth factor I and II on DNA synthesis and proliferation in primary cultures of adult rat hepatocytes. Eur J Pharmacol 1998;354:271–281.PubMedGoogle Scholar
  11. 11.
    Stolz DB, Michalopoulos GK. Comparative effects of hepatocyte growth factor and epidermal growth factor on motility, morphology, mitogenesis, and signal transduction of primary rat hepatocytes. J Cell Biochem 1994;55:445–464.PubMedGoogle Scholar
  12. 12.
    Michalopoulos GK, Bowen WC, Zajac VF, et al. Morphogenetic events in mixed cultures of rat hepatocytes and nonparenchymal cells maintained in biological matrices in the presence of hepatocyte growth factor and epidermal growth factor. Hepatology 1999;29:90–100.PubMedGoogle Scholar
  13. 13.
    Webster CR, Anwer MS. Phosphoinositide 3-kinase, but not mitogen-activated protein kinase, pathway is involved in hepatocyte growth factor-mediated protection against bile acid-induced apoptosis in cultured rat hepatocytes. Hepatology 2001;33:608–615.PubMedGoogle Scholar
  14. 14.
    Wang X, DeFrances MC, Dai Y, et al. A mechanism of cell survival: sequestration of Fas by the HGF receptor Met. Molecular Cell 2002;9:411–421.PubMedGoogle Scholar
  15. 15.
    Naldini L, Vigna E, Narsimhan RP, et al. Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene 1991;6:501–504.PubMedGoogle Scholar
  16. 16.
    Uehara Y, Minowa O, Mori C, et al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 1995;373:702–705.PubMedGoogle Scholar
  17. 17.
    Schmidt C, Bladt F, Goedecke S, et al. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 1995;373:699–702.PubMedGoogle Scholar
  18. 18.
    Bladt F, Riethmacher D, Isenmann S, Aguzzi A, Birchmeier C. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 1995;376:768–771.PubMedGoogle Scholar
  19. 19.
    Suzuki K, Hayashi N, Yamada Y, et al. Expression of the c-met protooncogene in human hepatocellular carcinoma. Hepatology 1994;20:1231–1236.PubMedGoogle Scholar
  20. 20.
    Ueki T, Fujimoto J, Suzuki T, Yamamoto H, Okamoto E. Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma. Hepatology 1997;25:862–866.PubMedGoogle Scholar
  21. 21.
    Tavian D, De Petro G, Benetti A, Portolani N, Giulini SM, Barlati S. u-PA and c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma. Int J Cancer 2000;87:644–649.PubMedGoogle Scholar
  22. 22.
    Park WS, Dong SM, Kim SY, et al. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res 1999;59:307–310.PubMedGoogle Scholar
  23. 23.
    Collonge-Rame MA, Bresson-Hadni S, Koch S, et al. Pattern of chromosomal imbalances in non-B virus related hepatocellular carcinoma detected by comparative genomic hybridization. Cancer Genet Cytogenet 2001;127:49–52.PubMedGoogle Scholar
  24. 24.
    Rao UN, Gollin SM, Beaves S, Cieply K, Nalesnik M, Michalopoulos GK. Comparative genomic hybridization of hepatocellular carcinoma: correlation with fluorescence in situ hybridization in paraffin-embedded tissue. Molecular Diag 2001;6:27–37.Google Scholar
  25. 25.
    Kiss A, Wang NJ, Xie JP, Thorgeirsson SS. Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met, TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. Clin Cancer Res 1997;3:1059–1066.PubMedGoogle Scholar
  26. 26.
    Bell A, Chen Q, DeFrances MC, Michalopoulos GK, Zarnegar R. The five amino aciddeleted isoform of hepatocyte growth factor promotes carcinogenesis in transgenic mice. Oncogene 1999;18:887–895.PubMedGoogle Scholar
  27. 27.
    Brown KD. The epidermal growth factor/transforming growth factor-alpha family and their receptors. Eur J Gastroenterol Hepatol 1995;7:914–922.PubMedGoogle Scholar
  28. 28.
    Komuves LG, Feren A, Jones AL, Fodor E. Expression of epidermal growth factor and its receptor in cirrhotic liver disease. J Histochem Cytochem 2000;48:821–830.PubMedGoogle Scholar
  29. 29.
    Motoo Y, Sawabu N, Nakanuma Y. Expression of epidermal growth factor and fibroblast growth factor in human hepatocellular carcinoma: an immunohistochemical study. Liver 1991;11:272–277.PubMedGoogle Scholar
  30. 30.
    Hisaka T, Yano H, Haramaki M, Utsunomiya I, Kojiro M. Expressions of epidermal growth factor family and its receptor in hepatocellular carcinoma cell lines: relationship to cell proliferation. Int J Oncol 1999;14: 453–460.PubMedGoogle Scholar
  31. 31.
    Lee GH, Merlino G, Fausto N. Development of liver tumors in transforming growth sfactor alpha transgenic mice. Cancer Res 1992;52:5162–5170.PubMedGoogle Scholar
  32. 32.
    Webber EM, Wu JC, Wang L, Merlino G, Fausto N. Overexpression of transforming growth factor-alpha causes liver enlargement and increased hepatocyte proliferation in transgenic mice. Am J Pathol 1994;145:398–408.PubMedGoogle Scholar
  33. 33.
    Hsia CC, Axiotis CA, Di Bisceglie AM, Tabor E. Transforming growth factor-alpha in human hepatocellular carcinoma and coexpression with hepatitis B surface antigen in adjacent liver. Cancer 1992;70:1049–1056.PubMedGoogle Scholar
  34. 34.
    Collier JD, Guo K, Gullick WJ, Bassendine MF, Burt AD. Expression of transforming growth factor alpha in human hepatocellular carcinoma. Liver 1993;13:151–155.PubMedGoogle Scholar
  35. 35.
    Schaff Z, Hsia CC, Sarosi I, Tabor E. Overexpression of transforming growth factor-alpha in hepatocellular carcinoma and focal nodular hyperplasia from European patients. Hum Pathol 1994;25:644–651.PubMedGoogle Scholar
  36. 36.
    Chung YH, Kim JA, Song BC, et al. Expression of transforming growth factor-alpha mRNA in livers of patients with chronic viral hepatitis and hepatocellular carcinoma. Cancer 2000;89:977–982.PubMedGoogle Scholar
  37. 37.
    Harada K, Shiota G, Kawasaki H. Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma. Liver 1999;19:318–325.PubMedGoogle Scholar
  38. 38.
    Ito Y, Takeda T, Sakon M, et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer 2001;84:1377–1383.PubMedGoogle Scholar
  39. 39.
    Morimitsu Y, Hsia CC, Kojiro M, Tabor E. Nodules of less-differentiated tumor within or adjacent to hepatocellular carcinoma: relative expression of transforming growth factor-alpha and its receptor in the different areas of tumor. Hum Pathol 1995;26: 1126–1132.PubMedGoogle Scholar
  40. 40.
    Hamazaki K, Yunoki Y, Tagashira H, Mimura T, Mori M, Orita K. Epidermal growth factor receptor in human hepatocellular carcinoma. Cancer Detect Prev 1997;21:355–360.PubMedGoogle Scholar
  41. 41.
    Baxter RC. Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol Endocrinol Metab 2000;278:E967–E976.PubMedGoogle Scholar
  42. 42.
    Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Nat Cancer Inst 2000;92:1472–1489.PubMedGoogle Scholar
  43. 43.
    Giovannone B, Scaldaferri ML, Federici M, et al. Insulin receptor substrate (IRS) transduction system: distinct and overlapping signaling potential. Diabetes Metab Res Rev 2000;16:434–441.PubMedGoogle Scholar
  44. 44.
    Jirtle RL. Genomic imprinting and cancer. Exp Cell Res 1999;248:18–24.PubMedGoogle Scholar
  45. 45.
    Kalscheuer VM, Mariman EC, Schepens MT, Rehder H, Ropers HH. The insulin-like growth factor type-2 receptor gene is imprinted in the mouse but not in humans. Nat Genet 1993;5:74–78.PubMedGoogle Scholar
  46. 46.
    Takeda S, Kondo M, Kumada T, et al. Allelic-expression imbalance of the insulin-like growth factor 2 gene in hepatocellular carcinoma and underlying disease. Oncogene 1996;12:1589–1592.PubMedGoogle Scholar
  47. 47.
    Aihara T, Noguchi S, Miyoshi Y, et al. Allelic imbalance of insulin-like growth factor II gene expression in cancerous and precancerous lesions of the liver. Hepatology 1998;28:86–89.PubMedGoogle Scholar
  48. 48.
    Sohda T, Yun K, Iwata K, Soejima H, Okumura M. Increased expression of insulin-like growth factor 2 in hepatocellular carcinoma is primarily regulated at the transcriptional level. Lab Invest 1996;75:307–311.PubMedGoogle Scholar
  49. 49.
    Ng IO, Lee JM, Srivastava G, Ng M. Expression of insulin-like growth factor II mRNA in hepatocellular carcinoma. J Gastroenterol Hepatol 1998;13:152–157.PubMedGoogle Scholar
  50. 50.
    D’Errico A, Grigioni WF, Fiorentino M, et al. Expression of insulin-like growth factor II (IGF-II) in human hepatocellular carcinomas: an immunohistochemical study. Pathol Int 1994;44:131–137.PubMedGoogle Scholar
  51. 51.
    Gong Y, Cui L, Minuk GY. The expression of insulin-like growth factor binding proteins in human hepatocellular carcinoma. Mol Cell Biochem 2000;207:101–104.PubMedGoogle Scholar
  52. 52.
    Okabe H, Satoh S, Kato T, et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 2001;61:2129–2137.PubMedGoogle Scholar
  53. 53.
    Hanafusa T, Yumoto Y, Nouso K, et al. Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Lett 2002;176:149–158.PubMedGoogle Scholar
  54. 54.
    Sasaki Y, Zhang XF, Nishiyama M, Avruch J, Wands JR. Expression and phosphorylation of insulin receptor substrate 1 during rat liver regeneration. J Biol Chem 1993;268:3805–3808.PubMedGoogle Scholar
  55. 55.
    Tanaka S, Mohr L, Schmidt EV, Sugimachi K, Wands JR. Biological effects of human insulin receptor substrate-1 overexpression in hepatocytes. Hepatology 1997;26:598–604.PubMedGoogle Scholar
  56. 56.
    Nishiyama M, Wands JR. Cloning and increased expression of an insulin receptor substrate-1-like gene in human hepatocellular carcinoma. Biochem Biophys Res Comm 1992;183:280–285.PubMedGoogle Scholar
  57. 57.
    Fry MJ. Structure, regulation and function of phosphoinositide 3-kinases. Biochim Biophys Acta 1994;1226:237–268.PubMedGoogle Scholar
  58. 58.
    Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489–501.PubMedGoogle Scholar
  59. 59.
    Toker A, Newton AC. Cellular signaling: pivoting around PDK-1. Cell 2000;103:185–188.PubMedGoogle Scholar
  60. 60.
    West KA, Castillo SS, Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Res Updates 2002;5:234–248.Google Scholar
  61. 61.
    Sun H, Lesche R, Li DM, et al. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Nat Acad Sci USA 1999;96:6199–6204.PubMedGoogle Scholar
  62. 62.
    Skouteris GG, Georgakopoulos E. Hepatocyte growth factor-induced proliferation of primary hepatocytes is mediated by activation of phosphatidylinositol 3-kinase. Biochem Biophys Res Comm 1996;218:229–233.PubMedGoogle Scholar
  63. 63.
    Hong F, Nguyen VA, Shen X, Kunos G, Gao B. Rapid activation of protein kinase B/Akt has a key role in antiapoptotic signaling during liver regeneration. Biochem Biophys Res Comm 2000;279:974–979.PubMedGoogle Scholar
  64. 64.
    Fruman DA, Mauvais-Jarvis F, Pollard DA, et al. Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 alpha. Nat Genet 2000;26:379–382.PubMedGoogle Scholar
  65. 65.
    Thorgeirsson SS, Teramoto T, Factor VM. Dysregulation of apoptosis in hepatocellular carcinoma. Semin Liver Dis 1998;18:115–122.PubMedGoogle Scholar
  66. 66.
    Yao YJ, Ping XL, Zhang H, et al. PTEN/MMAC1 mutations in hepatocellular carcinomas. Oncogene 1999;18:3181–3185.PubMedGoogle Scholar
  67. 67.
    Wan XW, Jiang M, Cao HF, et al. The alteration of PTEN tumor suppressor expression and its association with the histopathological features of human primary hepatocellular carcinoma. J Cancer Res Clin Oncol 2003;129:100–106.PubMedGoogle Scholar
  68. 68.
    Hu TH, Huang CC, Lin PR, et al. Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer 2003;97:1929–1940.PubMedGoogle Scholar
  69. 69.
    Podsypanina K, Ellenson LH, Nemes A, et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Nat Acad Sci USA 1999;96:1563–1568.PubMedGoogle Scholar
  70. 70.
    Smalley MJ, Dale TC. Wnt signalling in mammalian development and cancer. Cancer Metastasis Rev 1999;18:215–230.PubMedGoogle Scholar
  71. 71.
    Monga SP, Pediaditakis P, Mule K, Stolz DB, Michalopoulos GK. Changes in WNT/beta-catenin pathway during regulated growth in rat liver regeneration. Hepatology 2001;33:1098–1109.PubMedGoogle Scholar
  72. 72.
    Behrens J. Control of beta-catenin signaling in tumor development. Ann NY Acad Sci 2000;910:21–33; discussion 33–35.PubMedGoogle Scholar
  73. 73.
    Monga SP, Mars WM, Pediaditakis P, et al. Hepatocyte growth factor induces Wnt-independent nuclear translocation of beta-catenin after Met-beta-catenin dissociation in hepatocytes. Cancer Res 2002;62:2064–2071.PubMedGoogle Scholar
  74. 74.
    He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science 1998;281:1509–1512.PubMedGoogle Scholar
  75. 75.
    Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398:422–426.PubMedGoogle Scholar
  76. 76.
    Cui J, Zhou X, Liu Y, Tang Z. Mutation and overexpression of the beta-catenin gene may play an important role in primary hepatocellular carcinoma among Chinese people. J Cancer Res Clin Oncol 2001;127:577–581.PubMedGoogle Scholar
  77. 77.
    Hsu HC, Jeng YM, Mao TL, Chu JS, Lai PL, Peng SY. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol 2000;157:763–770.PubMedGoogle Scholar
  78. 78.
    Prange W, Breuhahn K, Fischer F, et al. Beta-catenin accumulation in the progression of human hepatocarcinogenesis correlates with loss of E-cadherin and accumulation of p53, but not with expression of conventional WNT-1 target genes. J Pathol 2003;201:250–259.PubMedGoogle Scholar
  79. 79.
    Ban KC, Singh H, Krishnan R, Seow HF. GSK-3beta phosphorylation and alteration of beta-catenin in hepatocellular carcinoma. Cancer Lett 2003;199:201–208.PubMedGoogle Scholar
  80. 80.
    Chen TC, Hsieh LL, Ng KF, Jeng LB, Chen MF. Absence of APC gene mutation in the mutation cluster region in hepatocellular carcinoma. Cancer Lett 1998;134:23–28.PubMedGoogle Scholar
  81. 81.
    Piao Z, Kim H, Jeon BK, Lee WJ, Park C. Relationship between loss of heterozygosity of tumor suppressor genes and histologic differentiation in hepatocellular carcinoma. Cancer 1997;80:865–872.PubMedGoogle Scholar
  82. 82.
    Su LK, Abdalla EK, Law CH, Kohlmann W, Rashid A, Vauthey JN. Biallelic inactivation of the APC gene is associated with hepatocellular carcinoma in familial adenomatous polyposis coli. Cancer 2001;92:332–339.PubMedGoogle Scholar
  83. 83.
    Satoh S, Daigo Y, Furukawa Y, et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 2000;24:245–250.PubMedGoogle Scholar
  84. 84.
    Laurent-Puig P, Legoix P, Bluteau O, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001;120:1763–1773.PubMedGoogle Scholar
  85. 85.
    Shibata T, Chuma M, Kokubu A, Sakamoto M, Hirohashi S. EBP50, a beta-catenin-associating protein, enhances Wnt signaling and is over-expressed in hepatocellular carcinoma. Hepatology 2003;38:178–186.PubMedGoogle Scholar
  86. 86.
    Slagle BL, Zhou YZ, Birchmeier W, Scorsone KA. Deletion of the E-cadherin gene in hepatitis B virus-positive Chinese hepatocellular carcinomas. Hepatology 1993;18:757–762.PubMedGoogle Scholar
  87. 87.
    Matsumura T, Makino R, Mitamura K. Frequent down-regulation of E-cadherin by genetic and epigenetic changes in the malignant progression of hepatocellular carcinomas. Clin Cancer Res 2001;7:594–599.PubMedGoogle Scholar
  88. 88.
    Endo K, Ueda T, Ueyama J, Ohta T, Terada T. Immunoreactive E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin proteins in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, and patients’ survival. Hum Pathol 2000;31:558–565.PubMedGoogle Scholar
  89. 89.
    Kanai Y, Ushijima S, Hui AM, et al. The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas. Int J Cancer 1997;71:355–359.PubMedGoogle Scholar
  90. 90.
    Jiao W, Miyazaki K, Kitajima Y. Inverse correlation between E-cadherin and Snail expression in hepatocellular carcinoma cell lines in vitro and in vivo. Br J Cancer 2002;86:98–101.PubMedGoogle Scholar
  91. 91.
    Li LC, Chui RM, Sasaki M, et al. A single nucleotide polymorphism in the E-cadherin gene promoter alters transcriptional activities. Cancer Res 2000;60:873–876.PubMedGoogle Scholar
  92. 92.
    Cadoret A, Ovejero C, Saadi-Kheddouci S, et al. Hepatomegaly in transgenic mice expressing an oncogenic form of beta-catenin. Cancer Res 2001;61:3245–3249.PubMedGoogle Scholar
  93. 93.
    Harada N, Miyoshi H, Murai N, et al. Lack of tumorigenesis in the mouse liver after adenovirus-mediated expression of a dominant stable mutant of beta-catenin. Cancer Res 2002;62:1971–1977.PubMedGoogle Scholar
  94. 94.
    Pruitt K, Der CJ. Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett 2001;171:1–10.PubMedGoogle Scholar
  95. 95.
    Auer KL, Contessa J, Brenz-Verca S, et al. The Ras/Rac1/Cdc42/SEK/JNK/c-Jun cascade is a key pathway by which agonists stimulate DNA synthesis in primary cultures of rat hepatocytes. Mol Biol Cell 1998;9:561–573.PubMedGoogle Scholar
  96. 96.
    Cruise JL, Muga SJ, Lee YS, Michalopoulos GK. Regulation of hepatocyte growth: alpha-1 adrenergic receptor and ras p21 changes in liver regeneration. J Cell Physiol 1989;140:195–201.PubMedGoogle Scholar
  97. 97.
    Ng YK, Taborn G, Ahmad I, Radosevich J, Bauer K, Iannaccone P. Spatiotemporal changes in Ha-ras p21 expression through the hepatocyte cell cycle during liver regeneration. Dev Biol 1992;150:352–362.PubMedGoogle Scholar
  98. 98.
    Ellis CA, Clark G. The importance of being K-Ras. Cell Signal 2000;12:425–434.PubMedGoogle Scholar
  99. 99.
    Evans DM, Williams WJ, Kung IT. Angiosarcoma and hepatocellular carcinoma in vinyl chloride workers. Histopathology 1983;7:377–388.PubMedGoogle Scholar
  100. 100.
    Weihrauch M, Benicke M, Lehnert G, Wittekind C, Wrbitzky R, Tannapfel A. Frequent k-ras-2 mutations and p16(INK4A)methylation in hepatocellular carcinomas in workers exposed to vinyl chloride. Br J Cancer 2001;84:982–989.PubMedGoogle Scholar
  101. 101.
    Tada M, Omata M, Ohto M. Analysis of ras gene mutations in human hepatic malignant tumors by polymerase chain reaction and direct sequencing. Cancer Res 1990;50:1121–1124.PubMedGoogle Scholar
  102. 102.
    Leon M, Kew MC. Analysis of ras gene mutations in hepatocellular carcinoma in southern African blacks. Anticancer Res 1995;15:859–861.PubMedGoogle Scholar
  103. 103.
    Ogata N, Kamimura T, Asakura H. Point mutation, allelic loss and increased methylation of c-Ha-ras gene in human hepatocellular carcinoma. Hepatology 1991;13:31–37.PubMedGoogle Scholar
  104. 104.
    Nonomura A, Ohta G, Hayashi M, et al. Immunohistochemical detection of ras oncogene p21 product in liver cirrhosis and hepatocellular carcinoma. Am J Gastroenterol 1987;82:512–518.PubMedGoogle Scholar
  105. 105.
    Jagirdar J, Nonomura A, Patil J, Thor A, Paronetto F. ras oncogene p21 expression in hepatocellular carcinoma. J Exper Pathol 1989;4:37–46.Google Scholar
  106. 106.
    Emi M, Fujiwara Y, Ohata H, et al. Allelic loss at chromosome band 8p21.3-p22 is associated with progression of hepatocellular carcinoma. Genes Chromosomes Cancer 1993;7:152–157.PubMedGoogle Scholar
  107. 107.
    Qin LX, Tang ZY, Sham JS, et al. The association of chromosome 8p deletion and tumor metastasis in human hepatocellular carcinoma. Cancer Res 1999;59:5662–5665.PubMedGoogle Scholar
  108. 108.
    Yuan BZ, Miller MJ, Keck CL, Zimonjic DB, Thorgeirsson SS, Popescu NC. Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res 1998;58:2196–2199.PubMedGoogle Scholar
  109. 109.
    Ng IO, Liang ZD, Cao L, Lee TK. DLC-1 is deleted in primary hepatocellular carcinoma and exerts inhibitory effects on the proliferation of hepatoma cell lines with deleted DLC-1. Cancer Res 2000;60:6581–6584.PubMedGoogle Scholar
  110. 110.
    Wong CM, Lee JM, Ching YP, Jin DY, Ng IO. Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma. Cancer Res 2003;63:7646–7651.PubMedGoogle Scholar
  111. 111.
    Lin YW, Sheu JC, Liu LY, et al. Loss of heterozygosity at chromosome 13q in hepatocellular carcinoma: identification of three independent regions. Eur J Cancer 1999;35:1730–1734.PubMedGoogle Scholar
  112. 112.
    Ching YP, Wong CM, Chan SF, et al. Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma. J Biol Chem 2003;278:10,824–10,830.PubMedGoogle Scholar
  113. 113.
    Eisenman RN. Deconstructing myc. Genes Develop 2001;15:2023–2030.PubMedGoogle Scholar
  114. 114.
    Pelengaris S, Rudolph B, Littlewood T. Action of Myc in vivo-proliferation and apoptosis. Current Opinion in Genet Develop 2000;10:100–105.Google Scholar
  115. 115.
    Chandar N, Lombardi B, Locker J. c-myc gene amplification during hepatocarcinogenesis by a choline-devoid diet. Proc Nat Acad Sci USA 1989;86:2703–2707.PubMedGoogle Scholar
  116. 116.
    Pascale RM, De Miglio MR, Muroni MR, et al. c-myc amplification in pre-malignant and malignant lesions induced in rat liver by the resistant hepatocyte model. Int J Cancer 1996;68:136–142.PubMedGoogle Scholar
  117. 117.
    Cartier N, Miquerol L, Tulliez M, et al. Diet-dependent carcinogenesis of pancreatic islets and liver in transgenic mice expressing oncogenes under the control of the L-type pyruvate kinase gene promoter. Oncogene 1992;7:1413–1422.PubMedGoogle Scholar
  118. 118.
    Fourel G, Trepo C, Bougueleret L, et al. Frequent activation of N-myc genes by hepadnavirus insertion in woodchuck liver tumours. Nature 1990;347:294–298.PubMedGoogle Scholar
  119. 119.
    Hsu T, Moroy T, Etiemble J, et al. Activation of c-myc by woodchuck hepatitis virus insertion in hepatocellular carcinoma. Cell 1988;55:627–635.PubMedGoogle Scholar
  120. 120.
    Abou-Elella A, Gramlich T, Fritsch C, Gansler T. c-myc amplification in hepatocellular carcinoma predicts unfavorable prognosis. Mod Pathol 1996;9:95–98.PubMedGoogle Scholar
  121. 121.
    Kawate S, Fukusato T, Ohwada S, Watanuki A, Morishita Y. Amplification of c-myc in hepatocellular carcinoma: correlation with clinicopathologic features, proliferative activity and p53 overexpression. Oncology 1999;57:157–163.PubMedGoogle Scholar
  122. 122.
    Gan FY, Gesell MS, Alousi M, Luk GD. Analysis of ODC and c-myc gene expression in hepatocellular carcinoma by in situ hybridization and immunohistochemistry. J Histochem Cytochem 1993;41:1185–1196.PubMedGoogle Scholar
  123. 123.
    Yuen MF, Wu PC, Lai VC, Lau JY, Lai CL. Expression of c-Myc, c-Fos, and c-jun in hepatocellular carcinoma. Cancer 2001;91:106–112.PubMedGoogle Scholar
  124. 124.
    Sampath D, Plunkett W. Design of new anticancer therapies targeting cell cycle checkpoint pathways. Curr Opin Oncol 2001;13:484–490.PubMedGoogle Scholar
  125. 125.
    Daujat S, Neel H, Piette J. MDM2: life without p53. Trends Genet 2001;17:459–464.PubMedGoogle Scholar
  126. 126.
    Kishimoto Y, Shiota G, Kamisaki Y, et al. Loss of the tumor suppressor p53 gene at the liver cirrhosis stage in Japanese patients with hepatocellular carcinoma. Oncology 1997;54:304–310.PubMedGoogle Scholar
  127. 127.
    Tanaka S, Toh Y, Adachi E, Matsumata T, Mori R, Sugimachi K. Tumor progression in hepatocellular carcinoma may be mediated by p53 mutation. Cancer Res 1993;53:2884–2887.PubMedGoogle Scholar
  128. 128.
    Park NH, Chung YH, Youn KH, et al. Close correlation of p53 mutation to microvascular invasion in hepatocellular carcinoma. J Clin Gastroenterol 2001;33:397–401.PubMedGoogle Scholar
  129. 129.
    Yano M, Asahara T, Dohi K, Mizuno T, Iwamoto KS, Seyama T. Close correlation between a p53 or hMSH2 gene mutation in the tumor and survival of hepatocellular carcinoma patients. Int J Oncol 1999;14:447–451.PubMedGoogle Scholar
  130. 130.
    Ng IO, Fan ST. Is the p53 gene mutation of prognostic value in hepatocellular carcinoma? [letter; comment.]. Arch Surg 2000;135:1476.PubMedGoogle Scholar
  131. 131.
    Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991;350:429–431.PubMedGoogle Scholar
  132. 132.
    Ozturk M. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 1991;338:1356–1359.PubMedGoogle Scholar
  133. 133.
    Feitelson MA, Zhu M, Duan LX, London WT. Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene 1993;8:1109–1117.PubMedGoogle Scholar
  134. 134.
    Wang XW, Forrester K, Yeh H, Feitelson MA, Gu JR, Harris CC. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Nat Acad Sci USA 1994;91:2230–2234.PubMedGoogle Scholar
  135. 135.
    Becker SA, Lee TH, Butel JS, Slagle BL. Hepatitis B virus X protein interferes with cellular DNA repair. J Virol 1998;72:266–272.PubMedGoogle Scholar
  136. 136.
    Pogribny IP, James SJ. Reduction of p53 gene expression in human primary hepatocellular carcinoma is associated with promoter region methylation without coding region mutation. Cancer Lett 2002;176:169–174.PubMedGoogle Scholar
  137. 137.
    Bourdon JC, D’Errico A, Paterlini P, Grigioni W, May E, Debuire B. p53 protein accumulation in European hepatocellular carcinoma is not always dependent on p53 gene mutation. Gastroenterology 1995;108: 1176–1182.PubMedGoogle Scholar
  138. 138.
    Qiu SJ, Ye SL, Wu ZQ, Tang ZY, Liu YK. The expression of the mdm2 gene may be related to the aberration of the p53 gene in human hepatocellular carcinoma. J Cancer Res Clin Oncol 1998;124:253–258.PubMedGoogle Scholar
  139. 139.
    Endo K, Ueda T, Ohta T, Terada T. Protein expression of MDM2 and its clinicopathological relationships in human hepatocellular carcinoma. Liver 2000;20:209–215.PubMedGoogle Scholar
  140. 140.
    Nevins JR. The Rb/E2F pathway and cancer. Hum Mol Genet 2001;10:699–703.PubMedGoogle Scholar
  141. 141.
    Zhang X, Xu HJ, Murakami Y, et al. Deletions of chromosome 13q, mutations in Retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res 1994;54:4177–4182.PubMedGoogle Scholar
  142. 142.
    Ashida K, Kishimoto Y, Nakamoto K, et al. Loss of heterozygosity of the retinoblastoma gene in liver cirrhosis accompanying hepatocellular carcinoma. J Cancer Res Clin Oncol 1997;123:489–495.PubMedGoogle Scholar
  143. 143.
    Roncalli M, Borzio M, Bianchi P, Laghi L. Comprehensive allelotype study of hepatocellular carcinoma. Hepatology 2000;32:876.PubMedGoogle Scholar
  144. 144.
    Hada H, Koide N, Morita T, et al. Promoter-independent loss of mRNA and protein of the Rb gene in a human hepatocellular carcinoma. Hepatogastroenterology 1996;43:1185–1189.PubMedGoogle Scholar
  145. 145.
    Edamoto Y, Hara A, Biernat W, et al. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int J Cancer 2003;106:334–341.PubMedGoogle Scholar
  146. 146.
    Higashitsuji H, Itoh K, Nagao T, et al. Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nat Med 2000;6:96–99.PubMedGoogle Scholar
  147. 147.
    Fu XY, Wang HY, Tan L, Liu SQ, Cao HF, Wu MC. Overexpression of p28/gankyrin in human hepatocellular carcinoma and its clinical significance. W J Gastroenterol 2002;8:638–643.Google Scholar
  148. 148.
    Hui AM, Li X, Makuuchi M, Takayama T, Kubota K. Over-expression and lack of retinoblastoma protein are associated with tumor progression and metastasis in hepatocellular carcinoma. Int J Cancer 1999;84:604–608.PubMedGoogle Scholar
  149. 149.
    Naka T, Toyota N, Kaneko T, Kaibara N. Protein expression of p53, p21WAF1, and Rb as prognostic indicators in patients with surgically treated hepatocellular carcinoma. Anticancer Res 1998;18:555–564.PubMedGoogle Scholar
  150. 150.
    Zimonjic DB, Keck CL, Thorgeirsson SS, Popescu NC. Novel recurrent genetic imbalances in human hepatocellular carcinoma cell lines identified by comparative genomic hybridization. Hepatology 1999;29:1208–1214.PubMedGoogle Scholar
  151. 151.
    Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994;8:15–21.PubMedGoogle Scholar
  152. 152.
    Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996;85:27–37.PubMedGoogle Scholar
  153. 153.
    Bates S, Phillips AC, Clark PA, et al. p14ARF links the tumour suppressors RB and p53. Nature 1998;395:124–125.PubMedGoogle Scholar
  154. 154.
    Liew CT, Li HM, Lo KW, et al. High frequency of p16INK4A gene alterations in hepatocellular carcinoma. Oncogene 1999;18:789–795.PubMedGoogle Scholar
  155. 155.
    Jin M, Piao Z, Kim NG, et al. p16 is a major inactivation target in hepatocellular carcinoma. Cancer 2000;89:60–68.PubMedGoogle Scholar
  156. 156.
    Piao Z, Park C, Lee JS, Yang CH, Choi KY, Kim H. Homozygous deletions of the CDKN2 gene and loss of heterozygosity of 9p in primary hepatocellular carcinoma. Cancer Lett 1998;122:201–207.PubMedGoogle Scholar
  157. 157.
    Hui AM, Sakamoto M, Kanai Y, et al. Inactivation of p16INK4 in hepatocellular carcinoma. Hepatology 1996;24:575–579.PubMedGoogle Scholar
  158. 158.
    Hui AM, Shi YZ, Li X, Takayama T, Makuuchi M. Loss of p16(INK4) protein, alone and together with loss of retinoblastoma protein, correlate with hepatocellular carcinoma progression. Cancer Lett 2000;154:93–99.PubMedGoogle Scholar
  159. 159.
    Chaubert P, Gayer R, Zimmermann A, et al. Germ-line mutations of the p16INK4(MTS1) gene occur in a subset of patients with hepatocellular carcinoma. Hepatology 1997;25:1376–1381.PubMedGoogle Scholar
  160. 160.
    Lee TK, Man K, Ling MT, et al. Over-expression of Id-1 induces cell proliferation in hepatocellular carcinoma through inactivation of p16INK4a/RB pathway. Carcinogenesis 2003;24:1729–1736.PubMedGoogle Scholar
  161. 161.
    Dotto GP. p21(WAF1/Cip1): more than a break to the cell cycle? Biochim et Biophys Acta 2000;1471:M43–M56.Google Scholar
  162. 162.
    Hui AM, Kanai Y, Sakamoto M, Tsuda H, Hirohashi S. Reduced p21(WAF1/CIP1) expression and p53 mutation in hepatocellular carcinomas. Hepatology 1997;25:575–579.PubMedGoogle Scholar
  163. 163.
    Furutani M, Arii S, Tanaka H, et al. Decreased expression and rare somatic mutation of the CIP1/WAF1 gene in human hepatocellular carcinoma. Cancer Lett 1997;111:191–197.PubMedGoogle Scholar
  164. 164.
    Kobayashi S, Matsushita K, Saigo K, et al. P21WAF1/CIP1 messenger RNA expression in hepatitis B, C virus-infected human hepatocellular carcinoma tissues. Cancer 2001;91:2096–2103.PubMedGoogle Scholar
  165. 165.
    Qin LF, Ng IO. Expression of p27(KIP1) and p21(WAF1/CIP1) in primary hepatocellular carcinoma: clinicopathologic correlation and survival analysis. Hum Pathol 2001;32:778–784.PubMedGoogle Scholar
  166. 166.
    Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Develop 1999;13:1501–1512.PubMedGoogle Scholar
  167. 167.
    Philipp-Staheli J, Payne SR, Kemp CJ. p27(Kip1): regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exper Cell Res 2001;264:148–168.Google Scholar
  168. 168.
    Tannapfel A, Grund D, Katalinic A, et al. Decreased expression of p27 protein is associated with advanced tumor stage in hepatocellular carcinoma. Int J Cancer 2000;89:350–355.PubMedGoogle Scholar
  169. 169.
    Ito Y, Matsuura N, Sakon M, et al. Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence. Hepatology 1999;30:90–99.PubMedGoogle Scholar
  170. 170.
    Fiorentino M, Altimari A, D’Errico A, et al. Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma. Clin Cancer Res 2000;6:3966–3972.PubMedGoogle Scholar
  171. 171.
    Catzavelos C, Bhattacharya N, Ung YC, et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997;3:227–230.PubMedGoogle Scholar
  172. 172.
    Kusano N, Shiraishi K, Kubo K, Oga A, Okita K, Sasaki K. Genetic aberrations detected by comparative genomic hybridization in hepatocellular carcinomas: their relationship to clinicopathological features. Hepatology 1999;29:1858–1862.PubMedGoogle Scholar
  173. 173.
    Zhang YJ, Jiang W, Chen CJ, et al. Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem Biophys Res Commun 1993;196:010–1016.Google Scholar
  174. 174.
    Nishida N, Fukuda Y, Komeda T, et al. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res 1994;54:3107–3110.PubMedGoogle Scholar
  175. 175.
    Yamashita T, Kaneko S, Hashimoto S, et al. Serial analysis of gene expression in chronic hepatitis C and hepatocellular carcinoma. Biochem Biophys Res Commun 2001;282:647–654.PubMedGoogle Scholar
  176. 176.
    Deane NG, Parker MA, Aramandla R, et al. Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. Cancer Res 2001;61:5389–5395.PubMedGoogle Scholar
  177. 177.
    Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001;411:342–348.PubMedGoogle Scholar
  178. 178.
    Gupta S. Molecular steps of death receptor and mitochondrial pathways of apoptosis. Life Sci 2001;69:2957–2964.PubMedGoogle Scholar
  179. 179.
    Ni R, Tomita Y, Matsuda K, et al. Fas-mediated apoptosis in primary cultured mouse hepatocytes. Exper Cell Res 1994;215:332–337.Google Scholar
  180. 180.
    Ogasawara J, Watanabe-Fukunaga R, Adachi M, et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993;364:806–809.PubMedGoogle Scholar
  181. 181.
    Oberhammer FA, Pavelka M, Sharma S, et al. Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor beta 1. Proc Natl Acad Sci USA 1992;89:5408–5412.PubMedGoogle Scholar
  182. 182.
    Bissell DM, Roulot D, George J. Transforming growth factor beta and the liver. Hepatology 2001;34:859–867.PubMedGoogle Scholar
  183. 183.
    Zhang X, Wang T, Batist G, Tsao MS. Transforming growth factor beta 1 promotes spontaneous transformation of cultured rat liver epithelial cells. Cancer Res 1994;54:6122–6128.PubMedGoogle Scholar
  184. 184.
    Factor VM, Kao CY, Santoni-Rugiu E, Woitach JT, Jensen MR, Thorgeirsson SS. Constitutive expression of mature transforming growth factor beta 1 in the liver accelerates hepatocarcinogenesis in transgenic mice. Cancer Res 1997;57:2089–2095.PubMedGoogle Scholar
  185. 185.
    Ito N, Kawata S, Tamura S, et al. Elevated levels of transforming growth factor beta messenger RNA and its polypeptide in human hepatocellular carcinoma. Cancer Res 1991;51:4080–4083.PubMedGoogle Scholar
  186. 186.
    Shirai Y, Kawata S, Tamura S, et al. Plasma transforming growth factor-beta 1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases. Cancer 1994;73:2275–2279.PubMedGoogle Scholar
  187. 187.
    Sue SR, Chari RS, Kong FM, et al. Transforming growth factor-beta receptors and mannose 6-phosphate/insulin-like growth factor-II receptor expression in human hepatocellular carcinoma. Ann Surg 1995;222:171–178.PubMedGoogle Scholar
  188. 188.
    Furuta K, Misao S, Takahashi K, et al. Gene mutation of transforming growth factor beta1 type II receptor in hepatocellular carcinoma. Int J Cancer 1999;81:851–853.PubMedGoogle Scholar
  189. 189.
    Kawate S, Takenoshita S, Ohwada S, et al. Mutation analysis of transforming growth factor beta type II receptor, Smad2, and Smad4 in hepatocellular carcinoma. Int J Oncology 1999;14:127–131.Google Scholar
  190. 190.
    Yakicier MC, Irmak MB, Romano A, Kew M, Ozturk M. Smad2 and Smad4 gene mutations in hepatocellular carcinoma. Oncogene 1999;18:4879–4883.PubMedGoogle Scholar
  191. 191.
    Dennis PA, Rifkin DB. Cellular activation of latent transforming growth factor beta requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor. Proc Natl Acad Sci USA 1991;88:580–584.PubMedGoogle Scholar
  192. 192.
    Dahms NM, Lobel P, Kornfeld S. Mannose 6-phosphate receptors and lysosomal enzyme targeting. J Biol Chem 1989;264:12,115–12,118.PubMedGoogle Scholar
  193. 193.
    De Souza AT, Hankins GR, Washington MK, Fine RL, Orton TC, Jirtle RL. Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene 1995;10:1725–1729.PubMedGoogle Scholar
  194. 194.
    Piao Z, Choi Y, Park C, Lee WJ, Park JH, Kim H. Deletion of the M6P/IGF2r gene in primary hepatocellular carcinoma. Cancer Lett 1997;120:39–43.PubMedGoogle Scholar
  195. 195.
    Yamada T, De Souza AT, Finkelstein S, Jirtle RL. Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis. Proc Natl Acad Sci USA 1997;94:10,351–10,355.PubMedGoogle Scholar
  196. 196.
    Wada I, Kanada H, Nomura K, Kato Y, Machinami R, Kitagawa T. Failure to detect genetic alteration of the mannose-6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) gene in hepatocellular carcinomas in Japan. Hepatology 1999;29:1718–1721.PubMedGoogle Scholar
  197. 197.
    De Souza AT, Hankins GR, Washington MK, Orton TC, Jirtle RL. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet 1995;11:447–449.PubMedGoogle Scholar
  198. 198.
    Kaplowitz N. Cell death at the millennium. Implications for liver diseases. Clin Liver Dis 2000;4:1–23, v.PubMedGoogle Scholar
  199. 199.
    Natoli G, Ianni A, Costanzo A, et al. Resistance to Fas-mediated apoptosis in human hepatoma cells. Oncogene 1995;11:1157–1164.PubMedGoogle Scholar
  200. 200.
    Ito Y, Monden M, Takeda T, et al. The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma. Br J Cancer 2000;82:1211–1217.PubMedGoogle Scholar
  201. 201.
    Kubo K, Matsuzaki Y, Okazaki M, Kato A, Kobayashi N, Okita K. The Fas system is not significantly involved in apoptosis in human hepatocellular carcinoma. Liver 1998;18:117–123.PubMedGoogle Scholar
  202. 202.
    Lee SH, Shin MS, Lee HS, et al. Expression of Fas and Fas-related molecules in human hepatocellular carcinoma. Hum Pathol 2001;32:250–256.PubMedGoogle Scholar
  203. 203.
    Roskams T, Libbrecht L, Van Damme B, Desmet V. Fas and Fas ligand: strong coexpression in human hepatocytes surrounding hepatocellular carcinoma; can cancer induce suicide in peritumoural cells? J Pathol 2000;191:150–153.PubMedGoogle Scholar
  204. 204.
    Takehara T, Hayashi N. Fas and fas ligand in human hepatocellular carcinoma. J Gastroenterol 2001;36:727–728.PubMedGoogle Scholar
  205. 205.
    Ito T, Shiraki K, Sugimoto K, et al. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 2000;31:1080–1085.PubMedGoogle Scholar
  206. 206.
    Chen GG, Lai PB, Chan PK, et al. Decreased expression of Bid in human hepatocellular carcinoma is related to hepatitis B virus X protein. Eur J Cancer 2001;37:1695–1702.PubMedGoogle Scholar
  207. 207.
    Fujikawa K, Shiraki K, Sugimoto K, et al. Reduced expression of ICE/caspase1 and CPP32/caspase3 in human hepatocellular carcinoma. Anticancer Res 2000;20:1927–1932.PubMedGoogle Scholar
  208. 208.
    Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153–164.PubMedGoogle Scholar
  209. 209.
    Rojkind MaG, Patricia. The extracellular matrix of the liver. In: Arias IM, ed. The Liver Biology and Pathobiology. New York: Raven Press, 1994:843–868.Google Scholar
  210. 210.
    Martinez-Hernandez A, Delgado FM, Amenta PS. The extracellular matrix in hepatic regeneration. Localization of collagen types I, III, IV, laminin, and fibronectin. Lab Invest 1991;64:157–166.PubMedGoogle Scholar
  211. 211.
    Ruoslahti E. Integrins. J Clin Invest 1991;87:1–5.PubMedGoogle Scholar
  212. 212.
    Roskelley CD, Srebrow A, Bissell MJ. A hierarchy of ECM-mediated signalling regulates tissue-specific gene expression. Curr Opin Cell Biol 1995;7:736–747.PubMedGoogle Scholar
  213. 213.
    Frisch SM, Screaton RA. Anoikis mechanisms. Curr Opin Cell Biol 2001;13:555–562.PubMedGoogle Scholar
  214. 214.
    Rojkind MaG, Patricia. Pathophysiology fo liver fibrosis. In: Arias IM, ed. The Liver Biology and Pathobiology. Philadelphia: Lippincott Williams & Wilkins, 2001:721–738.Google Scholar
  215. 215.
    Le Bail B, Faouzi S, Boussarie L, Balabaud C, Bioulac-Sage P, Rosenbaum J. Extracellular matrix composition and integrin expression in early hepatocarcinogenesis in human cirrhotic liver. J Pathol 1997;181:330–337.PubMedGoogle Scholar
  216. 216.
    Torimura T, Ueno T, Kin M, et al. Coordinated expression of integrin alpha6beta1 and laminin in hepatocellular carcinoma. Hum Pathol 1997;28:1131–1138.PubMedGoogle Scholar
  217. 217.
    Murphy G, Gavrilovic J. Proteolysis and cell migration: creating a path? Curr Opin Cell Biol 1999;11:614–621.PubMedGoogle Scholar
  218. 218.
    Giannelli G, Bergamini C, Fransvea E, Marinosci F, Quaranta V, Antonaci S. Human hepatocellular carcinoma (HCC) cells require both alpha3beta1 integrin and matrix metalloproteinases activity for migration and invasion. Lab Invest 2001;81:613–627.PubMedGoogle Scholar
  219. 219.
    Nakashima O, Kojiro M. Recurrence of hepatocellular carcinoma: multicentric occurrence or intrahepatic metastasis? A viewpoint in terms of pathology. J Hepatobiliary Pancreat Surg 2001;8:404–409.PubMedGoogle Scholar
  220. 220.
    Kirimlioglu H, Dvorchick I, Ruppert K, et al. Hepatocellular carcinomas in native livers from patients treated with orthotopic liver transplantation: biologic and therapeutic implications. Hepatology 2001;34:502–510.PubMedGoogle Scholar
  221. 221.
    Rudolph KL, Trautwein C, Kubicka S, et al. Differential regulation of extracellular matrix synthesis during liver regeneration after partial hepatectomy in rats. Hepatology 1999;30:1159–1166.PubMedGoogle Scholar
  222. 222.
    Kim TH, Mars WM, Stolz DB, Michalopoulos GK. Expression and activation of pro-MMP-2 and pro-MMP-9 during rat liver regeneration. Hepatology 2000;31:75–82.PubMedGoogle Scholar
  223. 223.
    Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997;72:1–22.PubMedGoogle Scholar
  224. 224.
    Mars WM, Zarnegar R, Michalopoulos GK. Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. Am J Pathol 1993; 143: 949–958.PubMedGoogle Scholar
  225. 225.
    Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem 1997;378:151–160.PubMedGoogle Scholar
  226. 226.
    McCawley LJ, Matrisian LM. Matrix metalloproteinases: they’re not just for matrix anymore! Curr Opin Cell Biol 2001;13:534–540.PubMedGoogle Scholar
  227. 227.
    Morita Y, Hayashi Y, Wang Y, et al. Expression of urokinase-type plasminogen activator receptor in hepatocellular carcinoma. Hepatology 1997;25:856–861.PubMedGoogle Scholar
  228. 228.
    Ashida K, Nakatsukasa H, Higashi T, et al. Cellular distribution of 92-kd type IV collagenase/gelatinase B in human hepatocellular carcinoma. Am J Pathol 1996;149:1803–1811.PubMedGoogle Scholar
  229. 229.
    Arii S, Mise M, Harada T, et al. Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential. Hepatology 1996;24:316–322.PubMedGoogle Scholar
  230. 230.
    Sakamoto Y, Mafune K, Mori M, et al. Overexpression of MMP-9 correlates with growth of small hepatocellular carcinoma. Int J Oncol 2000;17:237–743.PubMedGoogle Scholar
  231. 231.
    Giannelli G, Bergamini C, Marinosci F, et al. Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. Int J Cancer 2002;97:425–431.PubMedGoogle Scholar
  232. 232.
    Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249–257.PubMedGoogle Scholar
  233. 233.
    Sugimachi K, Tanaka S, Terashi T, Taguchi K, Rikimaru T. The mechanisms of angiogenesis in hepatocellular carcinoma: angiogenic switch during tumor progression.Surgery 2002;131:S135–S141.PubMedGoogle Scholar
  234. 234.
    Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascularspecific growth factors and blood vessel formation. Nature 2000;407:242–248.PubMedGoogle Scholar
  235. 235.
    Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocrine Rev 1997;18:4–25.Google Scholar
  236. 236.
    Ng IO, Poon RT, Lee JM, Fan ST, Ng M, Tso WK. Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. Am J Clin Pathol 2001;116:838–845.PubMedGoogle Scholar
  237. 237.
    Miura H, Miyazaki T, Kuroda M, et al. Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J Hepatol 1997;27:854–861.PubMedGoogle Scholar
  238. 238.
    Chow NH, Hsu PI, Lin XZ, et al. Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: an immunohistochemical study. Hum Pathol 1997;28:698–703.PubMedGoogle Scholar
  239. 239.
    Moon WS, Rhyu KH, Kang MJ, et al. Overexpression of VEGF and angiopoietin 2:a key to high vascularity of hepatocellular carcinoma? Mod Pathol 2003;16:552–557.PubMedGoogle Scholar
  240. 240.
    Shimamura T, Saito S, Morita K, et al. Detection of vascular endothelial growth factor and its receptor expression in human hepatocellular carcinoma biopsy specimens. J Gastroenterol Hepatol 2000;15:640–646.PubMedGoogle Scholar
  241. 241.
    Loughna S, Sato TN. Angiopoietin and Tie signaling pathways in vascular development. Matrix Biol 2001;20:319–325.PubMedGoogle Scholar
  242. 242.
    Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands JR. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest 1999;103:341–345.PubMedGoogle Scholar
  243. 243.
    Tanaka S, Sugimachi K, Yamashita Yi Y, et al. Tie2 vascular endothelial receptor expression and function in hepatocellular carcinoma. Hepatology 2002;35:861–867.PubMedGoogle Scholar
  244. 244.
    Soff GA. Angiostatin and angiostatin-related proteins. Cancer Metastasis Rev 2000;19:97–107.PubMedGoogle Scholar
  245. 245.
    Dong Z, Kumar R, Yang X, Fidler IJ. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 1997;88:801–810.PubMedGoogle Scholar
  246. 246.
    Gorrin Rivas MJ, Arii S, Furutani M, et al. Expression of human macrophage metalloelastase gene in hepatocellular carcinoma: correlation with angiostatin generation and its clinical significance. Hepatology 1998;28:986–993.PubMedGoogle Scholar
  247. 247.
    Suehiro T, Terashi T, Shiotani S, Soejima Y, Sugimachi K. Liver transplantation for hepatocellular carcinoma. Surgery 2002;131:S190–S194.PubMedGoogle Scholar
  248. 248.
    Bergsland EK, Venook AP. Hepatocellular carcinoma. Curr Opin Oncol 2000;12:357–361.PubMedGoogle Scholar
  249. 249.
    Okuda K. Hepatocellular carcinoma. J Hepatol 2000;32:225–237.PubMedGoogle Scholar
  250. 250.
    Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1855–1859.PubMedGoogle Scholar
  251. 251.
    Omata M, Shiratori Y. Long-term effects of interferon therapy on histology and development of hepatocellular carcinoma in hepatitis C. J Gastroenterol Hepatol 2000;15:E134–E140.PubMedGoogle Scholar
  252. 252.
    Scott LJ, Perry CM. Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs 2002;62:507–556.PubMedGoogle Scholar
  253. 253.
    Muto Y, Moriwaki H, Ninomiya M, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 1996;334:1561–1567.PubMedGoogle Scholar
  254. 254.
    Muto Y, Moriwaki H, Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 1999;340:1046–1047.PubMedGoogle Scholar
  255. 255.
    Okuno M, Sano T, Matsushima-Nishiwaki R, et al. Apoptosis induction by acyclic retinoid: a molecular basis of ‘clonal deletion’ therapy for hepatocellular carcinoma. Japan J Clin Oncol 2001;31:359–362.Google Scholar
  256. 256.
    Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002;20:1692–1703.PubMedGoogle Scholar
  257. 257.
    Scollay R. Gene therapy: a brief overview of the past, present, and future. Ann NY Acad Sci 2001;953:26–30.PubMedGoogle Scholar
  258. 258.
    Qian C, Drozdzik M, Caselmann WH, Prieto J. The potential of gene therapy in the treatment of hepatocellular carcinoma. J Hepatol 2000;32:344–351.PubMedGoogle Scholar
  259. 259.
    Baselga J, Albanell J. Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol 2001;12:S35–S41.PubMedGoogle Scholar
  260. 260.
    Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958–2970.PubMedGoogle Scholar
  261. 261.
    Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol 2001;61:253–270.PubMedGoogle Scholar
  262. 262.
    Kin M, Torimura T, Ueno T, et al. Angiogenesis inhibitor TNP-470 suppresses the progression of experimentally-induced hepatocellular carcinoma in rats. Int J Oncol 2000;16:375–382.PubMedGoogle Scholar
  263. 263.
    Ikebe T, Yamamoto T, Kubo S, et al. Suppressive effect of the angiogenesis inhibitor TNP-470 on the development of carcinogen-induced hepatic nodules in rats. Japan J Cancer Res 1998;89:143–149.Google Scholar
  264. 264.
    Bu W, Tang ZY, Sun FX, et al. Effects of matrix metalloproteinase inhibitor BB-94 on liver cancer growth and metastasis in a patient-like orthotopic model LCI-D20. Hepatogastroenterology 1998;45:1056–1061.PubMedGoogle Scholar
  265. 265.
    Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295:2387–2392.PubMedGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2005

Authors and Affiliations

  • Marie C. DeFrances
    • 1
  • George K. Michalopoulos
    • 1
  1. 1.Department of PathologyUniversity of Pittsburgh School of MedicinePittsburgh

Personalised recommendations